Book contents
- Case Studies: Stahl’s Essential Psychopharmacology
- Case Studies: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- Contributors
- List of icons
- Abbreviations
- Case 1: Usage of esketamine spray for treatment-resistant major depressive disorder (MDD)
- Case 2: The man who is confused about his identity
- Case 3: Propane, shattered glass, and parasites
- Case 4: Hit by a car
- Case 5: Caring for the whole person
- Case 6: The man whom clozapine (Clozaril) could not touch
- Case 7: Where did her period go?
- Case 8: To dopamine or not to dopamine, that is the question
- Case 9: The one that came out of nowhere
- Case 10: Darth Vaper strikes again
- Case 11: First-time Mom’s struggle with postpartum post-traumatic stress disorder (PTSD)
- Case 12: Why so down?
- Case 13: It’s confusing, isn’t it?
- Case 14: The adolescent who just can’t stay awake
- Case 15: The lady with bipolar disorder (BP), borderline personality disorder (BPD), and myasthenia gravis (MG)
- Case 16: Spending money does not make a bipolar diagnosis
- Case 17: Pain makes me anxious, and anxiety gives me pain
- Case 18: The woman who couldn’t focus
- Case 19: The gentleman with sudden onset of akathisia on clozapine (Clozaril)
- Case 20: The pregnancy blues
- Case 21: The menopause blues
- Case 22: The lady who felt “funny” on the medication
- Case 23: Two ladies with bruises
- Case 24: The lady who was afraid for her kids
- Case 25: The woman whose kidneys could not handle lithium
- Case 26: The gentleman who was sober and could not focus
- Case 27: When the music does not stop
- Case 28: The man who tried to get it right
- Index of drug names
- Index of case studies
- References
Case 2: - The man who is confused about his identity
Published online by Cambridge University Press: 03 April 2024
By
Book contents
- Case Studies: Stahl’s Essential Psychopharmacology
- Case Studies: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- Contributors
- List of icons
- Abbreviations
- Case 1: Usage of esketamine spray for treatment-resistant major depressive disorder (MDD)
- Case 2: The man who is confused about his identity
- Case 3: Propane, shattered glass, and parasites
- Case 4: Hit by a car
- Case 5: Caring for the whole person
- Case 6: The man whom clozapine (Clozaril) could not touch
- Case 7: Where did her period go?
- Case 8: To dopamine or not to dopamine, that is the question
- Case 9: The one that came out of nowhere
- Case 10: Darth Vaper strikes again
- Case 11: First-time Mom’s struggle with postpartum post-traumatic stress disorder (PTSD)
- Case 12: Why so down?
- Case 13: It’s confusing, isn’t it?
- Case 14: The adolescent who just can’t stay awake
- Case 15: The lady with bipolar disorder (BP), borderline personality disorder (BPD), and myasthenia gravis (MG)
- Case 16: Spending money does not make a bipolar diagnosis
- Case 17: Pain makes me anxious, and anxiety gives me pain
- Case 18: The woman who couldn’t focus
- Case 19: The gentleman with sudden onset of akathisia on clozapine (Clozaril)
- Case 20: The pregnancy blues
- Case 21: The menopause blues
- Case 22: The lady who felt “funny” on the medication
- Case 23: Two ladies with bruises
- Case 24: The lady who was afraid for her kids
- Case 25: The woman whose kidneys could not handle lithium
- Case 26: The gentleman who was sober and could not focus
- Case 27: When the music does not stop
- Case 28: The man who tried to get it right
- Index of drug names
- Index of case studies
- References
Summary
Does ketamine or esketamine worsen dissociation in patients with post-traumatic stress disorder (PTSD)?
Keywords
- Type
- Chapter
- Information
- Case Studies: Stahl's Essential Psychopharmacology , pp. 21 - 38Publisher: Cambridge University PressPrint publication year: 2024
References
Albott, CS, Lim, KO, Forbes, MK, et al. Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatment-resistant depression. J Clin Psychiatry 2018; 79:17m11634CrossRefGoogle ScholarPubMed
Aleksandrova, LR, Phillips, AG, Wang, YT. Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism. J Psychiatry Neurosci 2017; 42:222–9CrossRefGoogle ScholarPubMed
Browne, CA, Lucki, I. Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants. Front Pharmacol 2013; 4:161CrossRefGoogle ScholarPubMed
Canuso, CM, Singh, JB, Fedgchin, M, et al. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry 2018; 175:620–30CrossRefGoogle ScholarPubMed
Collins, A, Rutter, S, Feder, A. Development of ketamine administration as a treatment for chronic PTSD. Psychiatric Annals 2020; 50:68–76CrossRefGoogle Scholar
Feder, A, Parides, MK, Murrough, JW, et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry 2014; 71:681–8CrossRefGoogle ScholarPubMed
Henter, ID, de Sousa, RT, Zarate, CA, Jr. Glutamatergic modulators in depression. Harv Rev Psychiatry 2018; 26:307–19CrossRefGoogle ScholarPubMed
Hidalgo, R, Hertzberg, MA, Mellman, T, et al. Nefazodone in post-traumatic stress disorder: results from six open-label trials. Int Clin Psychopharmacol 1999; 14:61–8CrossRefGoogle ScholarPubMed
Kew, JN, Kemp, JA. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl) 2005; 179:4–29CrossRefGoogle ScholarPubMed
Kim, J, Farchione, T, Potter, A, et al. Esketamine for treatment-resistant depression – first FDA-approved antidepressant in a new class. N Engl J Med 2019; 381:1–4CrossRefGoogle ScholarPubMed
Liriano, F, Hatten, C, Schwartz, TL. Ketamine as treatment for post-traumatic stress disorder: a review. Drugs Context 2019; 8:212–305CrossRefGoogle ScholarPubMed
Murrough, JW, Perez, AM, Pillemer, S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 2013; 74:250–6CrossRefGoogle ScholarPubMed
Rasmussen, KG. Ketamine for posttraumatic stress disorder. JAMA Psychiatry 2015; 72:94–5CrossRefGoogle ScholarPubMed
Sartori, SB, Singewald, N. Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. Pharmacol Ther 2019; 204:107402CrossRefGoogle ScholarPubMed
Sattar, Y, Wilson, J, Khan, AM, et al. A review of the mechanism of antagonism of N-methyl-D-aspartate receptor by ketamine in treatment-resistant depression. Cureus 2018; 10:e2652Google ScholarPubMed
Stahl, SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 5. Cambridge: Cambridge University Press, 2021CrossRefGoogle Scholar
VA/DoD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder. Washington, DC: Veterans’ Association, 2017Google Scholar